CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells

被引:6
|
作者
Wu, Wenjing [1 ,2 ]
Zhao, Jianli [1 ,2 ]
Xiao, Jianhong [3 ]
Wu, Weijun [1 ,4 ]
Xie, Limin [1 ]
Xie, Xiaojuan [1 ]
Yang, Chaoye [1 ]
Yin, Dong [1 ]
Hu, Kaishun [1 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Hong Kong Joint Lab RNA Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Oncol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Hematol, Shenzhen 518000, Guangdong, Peoples R China
[4] Univ South China, Affiliated Hosp 1, Dept Radiotherapy, Hengyang 421001, Peoples R China
基金
中国国家自然科学基金;
关键词
CHFR; PARylation; PARP1; RNF126; Ubiquitination; ADP-RIBOSYLATION; HOMOLOGOUS RECOMBINATION; E3; LIGASE; PROTEIN; UBIQUITINATION; CHECKPOINT; AXIN;
D O I
10.1016/j.bbrc.2021.08.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ring-finger protein 126 (RNF126), an E3 ubiquitin ligase, plays crucial roles in various biological processes, including cell proliferation, DNA damage repair, and intracellular vesicle trafficking. Whether RNF126 is modulated by posttranslational modifications is poorly understood. Here, we show that PARP1 interacts with and poly(ADP)ribosylates RNF126, which then recruits the PAR-binding E3 ubiquitin ligase CHFR to promote ubiquitination and degradation of RNF126. Moreover, RNF126 is required for the activation of ATR-Chk1 signaling induced by either irradiation (IR) or a PARP inhibitor (PARPi), and depletion of RNF126 increases the sensitivity of triple-negative breast cancer (TNBC) cells to PARPi treatment. Our findings suggest that PARPi-mediated upregulation of RNF126 protein stability contributes to TNBC cell resistance to PARPi. Therefore, targeting the E3 ubiquitin ligase RNF126 may be a novel treatment for overcoming the resistance of TNBC cells to PARPi in clinical trials. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 50 条
  • [1] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [2] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [3] Judy Garber on PARP inhibitors for triple-negative breast cancer
    Garber, Judy
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 814 - +
  • [4] Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
    Liu, Yajing
    Martin-Trevino, Rachel
    Shang, Li
    Davis, April
    Wicha, Max
    Liu, Suling
    Burness, Monika
    CANCER RESEARCH, 2015, 75
  • [5] RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy
    Liu, Wenjing
    Zheng, Min
    Zhang, Rou
    Jiang, Qiuyun
    Du, Guangshi
    Wu, Yingying
    Yang, Chuanyu
    Li, Fubing
    Li, Wei
    Wang, Luzhen
    Wu, Jiao
    Shi, Lei
    Li, Wenhui
    Zhang, Kai
    Zhou, Zhongmei
    Liu, Rong
    Gao, Yingzheng
    Huang, Xinwei
    Fan, Songqing
    Zhi, Xu
    Jiang, Dewei
    Chen, Ceshi
    ADVANCED SCIENCE, 2023, 10 (05)
  • [6] New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
    Han, Ye
    Yu, Xiaopeng
    Li, Shuqiang
    Tian, Ye
    Liu, Caigang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
    Yordanova, Mariya
    Hubert, Audrey
    Hassan, Saima
    PHARMACEUTICALS, 2021, 14 (12)
  • [9] PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
    Layman, Rachel M.
    Arun, Banu
    CANCER JOURNAL, 2021, 27 (01): : 67 - 75
  • [10] Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation
    Go, Ahra
    Jang, Jeong Woon
    Lee, Woori
    Ha, Jae Du
    Kim, Hyun Jin
    Nam, Hye Jin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 204